Tech Company Financing Transactions
Autolus Funding Round
Arix Bioscience, Cormorant Asset Management and Nextech Invest participated in a $80 million Series C capital raise for Autolus. The funding round closed on 9/28/2017.
Transaction Overview
Company Name
Announced On
9/28/2017
Transaction Type
Venture Equity
Amount
$80,000,000
Round
Series C
Investors
Proceeds Purpose
The funds raised will enable Autolus to establish clinical proof of concept for three novel haematological cancer programmes: AUTO2 in multiple myeloma, which recently completed the first-dose cohort of its Phase I/II study; AUTO3 which has initiated Phase I/II studies in diffuse large B cell lymphoma and paediatric acute lymphoblastic leukaemia; and AUTO4 in T-cell lymphoma which is ready for the clinic.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
191 Wood Ln. The Mediaworks White City
London, W12 7FP
UK
London, W12 7FP
UK
Phone
Website
Email Address
Overview
Autolus is at the forefront of a revolution in cancer treatment. Chimeric Antigen Receptor (CAR) T-cell therapies have been shown to be effective in some haematological malignancies and may have wide applications as a cancer treatment, with the potential to offer a cure.
Management Team
Title
Name
Email & Social
Browse more venture capital transactions:
Prev: 9/28/2017: Royole venture capital transaction
Next: 9/28/2017: Iris Plans venture capital transaction
Share this article
About Our Venture Capital Transactions Database
Our team works diligently to report on every notable VC transaction. VC transactions reported here come from a variety of public sources. The information is sourced from VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs